These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28843946)

  • 21. Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    Petta S; Marchesini G
    J Hepatol; 2017 Nov; 67(5):1122. PubMed ID: 28822589
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Recipient characteristics and morbidity and mortality after liver transplantation" [J hepatol 69 (2018) 43-50].
    Asrani SK; Saracino G; O'Leary JG; Gonzalez S; Kim PT; McKenna GJ; Klintmalm G; Trotter J
    J Hepatol; 2018 Oct; 69(4):989. PubMed ID: 30097328
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis" [J Hepatol 71 (2019) 763-772].
    Bonnin M; Fares N; Testoni B; Estornes Y; Weber K; Vanbervliet B; Lefrançois L; Garcia A; Kfoury A; Pez F; Coste I; Saintigny P; Viari A; Lang K; Guey B; Petrilli V; Hervieu V; Bancel B; Bartosch B; Durantel D; Renno T; Merle P; Lebecque S
    J Hepatol; 2020 Mar; 72(3):594. PubMed ID: 31780083
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    D'Amico G; Bernardi M; Angeli P
    J Hepatol; 2022 Mar; 76(3):757. PubMed ID: 34998627
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
    J Hepatol; 2017 Nov; 67(5):1123. PubMed ID: 28916407
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    Mookerjee RP; Mehta G; Balasubramaniyan V; Mohamed FEZ; Davies N; Sharma V; Iwakiri Y; Jalan R
    J Hepatol; 2017 Nov; 67(5):1124. PubMed ID: 28893453
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19].
    Salomone F; Pipitone RM; Longo M; Malvestiti F; Amorini AM; Distefano A; Casirati E; Ciociola E; Iraci N; Leggio L; Zito R; Vicario N; Saoca C; Männistö V; Pihlajamäki J; Qadri S; Yki-Järvinen H; Romeo S; Pennisi G; Cabibi D; Lazzarino G; Fracanzani AL; Dongiovanni P; Valenti L; Petta S; Volti GL; Grimaudo S
    J Hepatol; 2024 Feb; 80(2):378. PubMed ID: 38182533
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    Karampatou A; Han X; Kondili LA; Taliani G; Ciancio A; Morisco F; Critelli RM; Baraldi E; Bernabucci V; Troshina G; Guarino M; Tagliavini S; D'Ambrosio F; Bristot L; Turco L; Rosato S; Vella S; Trenti T; Neri I; La Marca A; Manthena S; Goldstein AS; Bruno S; Bao Y; Gonzalez YS; Villa E;
    J Hepatol; 2018 Apr; 68(4):867. PubMed ID: 29366584
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    de Franchis R; Bosch J; Garcia-Tsao G; Reiberger T; Ripoll C;
    J Hepatol; 2022 Jul; 77(1):271. PubMed ID: 35431106
    [No Abstract]   [Full Text] [Related]  

  • 30. Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    Wang YZ
    J Hepatol; 2022 Aug; 77(2):581. PubMed ID: 35525632
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1" [J Hepatol 69 (2018) 1110-1122].
    Qin JJ; Mao W; Wang X; Sun P; Cheng D; Tian S; Zhu XY; Yang L; Huang Z; Li H
    J Hepatol; 2019 Mar; 70(3):578-580. PubMed ID: 30616986
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Nov; 73(5):1295-1296. PubMed ID: 32921509
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2019 Mar; 70(3):581. PubMed ID: 30635242
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to "Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: Update 2016" [J. Clin. Exp. Hepatol. 6 (2016) 119-145].
    Puri P; Saraswat VA; Dhiman RK; Anand AC; Acharya SK; Singh SP; Chawla YK; Amarapurkar DN; Kumar A; Arora A; Dixit VK; Koshy A; Sood A; Duseja A; Kapoor D; Madan K; Srivastava A; Kumar A; Wadhawan M; Goel A; Verma A; Shalimar ; Pandey G; Malik R; Agrawal S
    J Clin Exp Hepatol; 2016 Sep; 6(3):263. PubMed ID: 29021664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corrigendum to ‘‘Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease” [J Hepatol 2015;63:1405–1412].
    J Hepatol; 2016 Apr; 64(4):989. PubMed ID: 27441324
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    Yang T; Poenisch M; Khanal R; Hu Q; Dai Z; Li R; Song G; Yuan Q; Yao Q; Shen X; Taubert R; Engel B; Jaeckel E; Vogel A; Falk CS; Schambach A; Gerovska D; Araúzo-Bravo MJ; Vondran FWR; Cantz T; Horscroft N; Balakrishnan A; Chevessier F; Ott M; Sharma AD
    J Hepatol; 2022 Jul; 77(1):270. PubMed ID: 35397937
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    Tsay HC; Yuan Q; Balakrishnan A; Kaiser M; Möbus S; Kozdrowska E; Farid M; Tegtmeyer PK; Borst K; Vondran FWR; Kalinke U; Kispert A; Manns MP; Ott M; Sharma AD
    J Hepatol; 2022 Jul; 77(1):269. PubMed ID: 35397938
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 Jul; 73(1):225-226. PubMed ID: 32360197
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series
    European Association For The Study Of The Liver
    J Hepatol; 2023 Feb; 78(2):452. PubMed ID: 36464532
    [No Abstract]   [Full Text] [Related]  

  • 40. Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
    J Hepatol; 2022 Mar; 76(3):755-756. PubMed ID: 34965902
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.